Karin E. Havenith
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 28, 2026
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.
Journal: Blood advances
Published: December 10, 2024
Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary.
Journal: Future oncology (London, England)
Published: November 07, 2024
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Journal: Cancer cell
Published: February 28, 2024
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Journal: bioRxiv : the preprint server for biology
Published: December 18, 2023
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies.
Journal: Molecular cancer therapeutics
Published: August 04, 2023
Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 27, 2023
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma.
Journal: Cancer chemotherapy and pharmacology
Published: June 14, 2022
Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
Journal: Molecular cancer therapeutics
Published: August 24, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Journal: The Lancet. Haematology
Published: January 14, 2021
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: January 07, 2021
Last Updated: 09/26/2026